IJCS | Volume 33, Nº3, May / June 2020

DOI: https://doi.org/10.36660/ijcs.20200070 Congestive heart failure (HF) is the end stage for many cardiac diseases. It is associated with high mortality and high hospital readmission rates, despite advances in pharmacological (sacubitril‑losartan, be t a - b l ocke r s and r en i n - ang i o t ens i n sys t em inhibitors) and non-pharmacological (defibrillators and resynchronizers) treatment. Therefore, it is natural that clinicians are interested in the improvement of diagnostic methods and efficient prognostic markers capable of identifying patients at higher risk, thus anticipating complications and providing treatment guidance. We cardiologists have long recognized biventricular dysfunction as a more severe and advanced form of HF, and brain natriuretic peptide (BNP) as a biochemical marker, used for both diagnostic and prognostic purposes. However, BNP are not yet widely used in daily clinical practice, probably due to overestimation of clinical parameters for the indication, conduction and determination of the therapy inmost services focused on these patients' assistance. The search for other methods with prognostic and diagnostic value for right ventricular dysfunction remains constant. Nevertheless, these methods must meet the requirements that current tests have failed to achieve: low cost, high specificity and sensitivity, reproducibility and no requirement of high technical knowledge to operate. Elastography has long been used by hepatologists in the evaluation of liver parenchyma stiffness. 1 This test assesses tissue stiffness using an ultrasound transducer, which measures low-frequency vibrations. There is a direct relationship between the parenchyma stiffness and the propagation of these vibrations registered by the device. The stiffer the hepatic parenchyma, the faster the vibrations are propagated. Often, this stiffness is associated with numerous factors such as fibrosis, inflammation, liver perfusion, fatty infiltration, cholestasis and congestion. Interestingly, the congestion that interfered in the results of elastography, during the investigation of liver diseases, called cardiologists’ attention. It was clear that there was an important correlation between increased liver stiffness and increased venocapillary pressure 2 and also the possibility of using this test to assess right ventricular performance. Ávila D et al., 3 in their excellent systematic review, selected 7 studies that compared hepatic elastography (HE) with the results of echocardiography and BNP, in patients with HF. They concluded that the use of this technique seems to improve the diagnostic power of increased right-sided filling cardiac pressures and could assist in the medical management of these patients, adding prognostic value at the moment of hospital discharge. However, they were careful in stating that these are not A definitive result, and further studies are needed for a better understanding of this issue. Elastography combined with ultrasound is a simple, fast, low-cost and noninvasive test, performed at the bedside. Still, several barriers have yet to be overcome: Regarding elastography, the method is examiner- dependent. Besides, it requires a device so that the measurements are obtained, and adequate training to mitigate the possibility of measuring errors. 233 EDITORIAL International Journal of Cardiovascular Sciences. 2020; 33(3):233-234 Mailing Address: Edison Migowski Rua Rodolpho Paulo Rocco, 255. Postal Code: 21941-590, Ilha do Fundão, Rio de Janeiro, RJ – Brazil E-mail: emigowski@gmail.com Hepatic Elastography in the Assessment of Heart Failure: Where We Came from and Where We Are Going Edison Migowsk i Hospital Universitário Clementino Fraga Filho – UFRJ, Rio de Janeiro, RJ – Brazil Heart Failure; Elasticity Imaging Techniques/methods; Hospitalization; Outcomes; Patient Readmission; Prognosis; Liver Diseases. Keywords